## Exhibit 107

United States of America ex rel. Ven-a-Care of the Florida Keys, Inc. v. Boehringer Ingelheim
Corp. et al.
Civil Action No. 07-10248-PBS

Exhibit to the July 24, 2009, Declaration of James J. Fauci In Support of Plaintiff's Motion for Partial Summary Judgment and In Opposition to the Roxane Defendants' Motion For Partial Summary Judgment From:

WATERER, JUDY **ROXUS** 

Sent:

Thursday, July 20, 2000 9:23 AM ROXUS

To: Cc: POWERS, JOHN SLS BIPUS MOT, AIV

Subject:

RE: Kaiser - CCP

Now - that's another situation... We can do something based on "meeting competition". We need to determine what their use is, what they will commit to in terms of conversion, and what we need to do the meet the competitive situation....

----Original Message-

POWERS, JOHN **ROXUS** From: Thursday, July 20, 2000 9:44 AM Sent: WATERER, JUDY **ROXUS** To: SLS BIPUS Cc: MOT, AIV

Subject:

Kaiser - CCP

Judy,

My conversation with Elizabeth did not go as planned Wednesday. I discussed the AWP spread, the additional price reduction, the market share program, the sole generic positioning, but after discussing the options with her boss Rich Lieblich, unless we will provide a fixed price, Roxane will not have a CCP agreement with Kaiser. Apparently BMS has provided Kaiser an attractive discounted fixed price agreement, so unless we beat it, we're left out.

## John R. Powers

Director, Contract Operations

Boehringer Ingelheim Pharmaceuticals Inc. and Roxane Laboratories, Inc.

Phone: 614/351-5445 Fax: 614/276-3786

Internet Address: jpowers@col.boehringer-ingelheim.com